Redefining Non-small Cell Lung Cancer: The Role of Histology. History of Therapy in Advanced NSCLC: FDA Approval Dates. ECOG 1594: What Did It Teach Us?. Bevacizumab in NSCLC: Key Clinical Outcomes. Grade 3-5 Non-hematologic Toxicity Associated With Bevacizumab. AVAIL Study Design. - PowerPoint PPT Presentation
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Redefining Non-small Cell Lung Cancer: The Role of Histology
History of Therapy in Advanced NSCLC: FDA Approval Dates
ECOG 1594: What Did It Teach Us?
Bevacizumab in NSCLC: Key Clinical Outcomes
Grade 3-5 Non-hematologic Toxicity Associated With
Bevacizumab
AVAIL Study Design
AVAIL: Progression-Free Survival
Study Design: Cisplatin/Pemetrexed
vs Cisplatin/Gemcitabine in First-line NSCLC
Cisplatin/Gemcitabine vs Cisplatin/Pemetrexed
in Advanced NSCLC
Toxicities Associated With Platinum-Based Combination
Chemotherapy in Advanced NSCLC
Phase 3 PointBreak Study Design
PointBreak: Overall Survival From Randomization (Intent-to-
Treat)
PointBreak: Prespecified Exploratory Analysis of KM OS from Randomization: Maintenance
Group
PointBreak: CTCAEs (Version 3) Possibly Related to Study Drug in Safety